Understanding therapeutic potential, microdosing, higher-dose experiences, safety, and the importance of what happens before and after
By Meg Reinis, LMFT | The Hive Therapy & Wellness Boutique
Psychedelics are often described as catalysts for healing. Research has found promising results for conditions including depression, distress associated with serious illness, and some substance-use disorders. Studies are also underway for PTSD and other mental-health concerns.
But a psychedelic experience is not automatically therapeutic simply because it is intense, emotional, spiritual, or insightful.
The substance is only one part of a much larger process.
In clinical research, psychedelic treatment generally includes screening, preparation, a carefully supported dosing session, and follow-up integration. The environment, therapeutic relationship, expectations, medical safety, and work that happens afterward may all influence the experience and its meaning.
Preparation helps create a safe and intentional container. Integration helps transform what happened into something that can be lived.
Without those pieces, a powerful experience may remain confusing, destabilizing, or disconnected from everyday life.
Why This Work Is Personal to Me
My interest in psychedelics did not begin as a professional specialization. It began with my own life.
I first used psychedelics as a teenager. Although I did not yet have the language to understand everything that was happening within me, the experience was profound. It helped me recognize that I needed support for my own trauma and eating disorder, and it became part of what led me toward therapy.
That experience did not heal everything. It opened a door.
Therapy gave me a place to begin understanding what had surfaced, to make meaning of my history, and to start building a different relationship with myself. Looking back, I can see that the psychedelic experience was a catalyst—but the healing required honesty, support, and continued work.
Years later, as an adult, I went through a period of grief that felt increasingly difficult to move through. I was doing many of the things we are told will help: going to therapy, exercising, journaling, reflecting, and trying to care for myself. Those practices mattered, but I still felt as though I were walking beneath a heavy cloud. I understood my grief, yet I was not experiencing the relief I was seeking.
I eventually returned to psychedelics within an intentional, therapeutic context. The experience did not erase my grief, but I felt an immediate opening—an internal shift that allowed some relief to enter. It felt like the beginning of moving the cloud I had been carrying.
What followed mattered just as much as the experience itself. I worked diligently on integration. I studied what had happened, paid attention to what the experience was asking of me, and practiced translating insight into my relationships, choices, boundaries, and daily life.
I also continued learning about the research, risks, ethics, preparation, and clinical applications of psychedelic work. I witnessed profound changes in other people, while also learning that powerful experiences can be confusing or destabilizing when people do not have adequate screening, support, or follow-through.
Eventually, I began working with clients who were preparing for psychedelic experiences obtained outside of my therapy services, as well as clients who wanted help integrating experiences they had already had. I saw people access grief, self-compassion, truth, and long-standing patterns in ways that felt different from ordinary conversation. I also saw that the lasting value did not come from the experience alone. It came from what they were willing and supported to do afterward.
This is why preparation and integration are central to the way I approach this work at The Hive. I do not view psychedelics as a shortcut, cure, or substitute for therapy. I see them as potential catalysts—experiences that may create an opening, illuminate what needs attention, or make another way of living feel possible.
The experience may open the door. Integration is how we learn to walk through it.
What Does “Therapeutic Use” Actually Mean?
The word psychedelic covers substances with different effects and risks. Classic psychedelics such as psilocybin and LSD primarily affect serotonin 2A receptors. MDMA is generally described as an empathogen or entactogen rather than a classic psychedelic. Ketamine and FDA-approved esketamine belong to a different drug class and have distinct medical protocols.
It is therefore misleading to discuss all psychedelic substances as though they are interchangeable.
Therapeutic use is also different from simply taking a substance and hoping that healing occurs. In controlled research, treatment typically includes:
- Careful medical and psychological screening
- Informed consent and discussion of risks
- Preparation with trained professionals
- A controlled setting with monitoring and support
- A known substance and standardized dose
- A plan for difficult or emergency reactions
- Follow-up assessment and integration
As of August 2026, the FDA continues to describe psychedelic medications such as psilocybin and MDMA as investigational rather than generally approved psychiatric treatments. The agency has accelerated some development programs and issued final guidance for clinical research, but accelerated review or “breakthrough” status is not the same as approval.
State laws also vary. Colorado has created a regulated natural-medicine program with licensed facilitators and healing centers. That does not mean every therapist, coach, retreat, private residence, or informal guide is authorized to provide regulated psychedelic services. Anyone considering this work should understand the laws, credentials, scope of practice, and emergency procedures that apply to the specific setting.
What Are the Potential Therapeutic Benefits?
The strongest contemporary evidence is not for psychedelics as universal wellness enhancers. It is for specific substances, populations, protocols, and clinical outcomes.
Psilocybin-assisted therapy has shown promising effects for major depression and treatment-resistant depression. Research has also found reductions in depression and anxiety among some people facing cancer or other life-threatening illness. Early studies have examined alcohol and tobacco use disorders, obsessive-compulsive symptoms, and other conditions.
Across these studies, participants sometimes report:
- Reduced depressive symptoms
- Reduced anxiety or existential distress
- Increased psychological flexibility
- A different relationship with painful thoughts and emotions
- Greater self-compassion or connection
- New perspective on long-standing patterns
- Increased motivation to change behavior
- A sense of meaning, acceptance, or emotional release
These outcomes are not guaranteed. Some studies are small, expectancy effects are difficult to eliminate, blinding is challenging, and research participants are carefully selected in ways that may not reflect ordinary community use.
Psychedelics may create a temporary period in which experience feels unusually vivid, emotionally open, or psychologically flexible. That opening can be useful—but what enters the opening matters. Supportive context, ethical care, and integration can help turn possibility into change.
Preparation: Building the Container Before the Experience
Preparation is much more than choosing an intention or assembling a playlist.
A systematized review of 83 sources found broad consensus that substance-assisted psychotherapy should include adequate preparation, including safety screening, attention to set and setting, physical and psychological preparation, discussion of therapist roles, and establishment of a therapeutic relationship.
Good preparation asks: Is this appropriate for this person, with this substance, at this time, in this setting?
Medical and psychological screening
Preparation should include an honest review of:
- Current and past psychiatric diagnoses
- Personal and family history of psychosis, mania, and bipolar disorder
- Suicidal thoughts, recent crises, and current stability
- Trauma history, dissociation, panic, and ability to self-regulate
- Cardiovascular, neurological, seizure, liver, and other relevant medical conditions
- Pregnancy or breastfeeding
- Current medications, supplements, and substance use
- Previous psychedelic experiences, including difficult or prolonged reactions
- Available support before, during, and after the experience
Medication decisions must be made with an appropriate prescriber. Abruptly stopping antidepressants, mood stabilizers, stimulants, benzodiazepines, lithium, or other medication can be dangerous. Interactions are substance-specific: a risk profile for psilocybin is not the same as one for MDMA, ayahuasca, ibogaine, or ketamine.
Psychological preparation
Preparation also helps someone become familiar with the territory of an altered state.
This may include:
- Clarifying hopes without demanding a particular outcome
- Identifying fears and protective responses
- Discussing what surrender means—and what it does not mean
- Practicing grounding, orienting, and asking for help
- Preparing for changes in time, identity, perception, and emotion
- Talking through consent, touch, boundaries, and the facilitator’s role
- Planning for difficult content without assuming every image is literal truth
- Establishing how the person will communicate distress or medical needs
An intention can provide direction, but it should not become a performance standard. “Show me how to heal” may create enormous pressure. A gentler intention might be: “Help me stay curious about what arises,” or “I am willing to listen without forcing an answer.”
Practical preparation
The practical container matters too: transportation, time away from work and caregiving, trusted support, food and sleep, emergency planning, and a calm period afterward. A person should not be expected to drive, make major decisions, care for children, or return immediately to ordinary responsibilities while impaired or emotionally vulnerable.
Preparation cannot guarantee a comfortable experience. It can reduce preventable risk and give the person more internal and external support if the experience becomes difficult.
Integration: Turning Insight Into a Life
Integration is the process of making sense of the experience and translating what was meaningful into everyday choices.
It is not the therapist declaring what a symbol meant. It is not treating every memory, vision, or belief as fact. And it is not encouraging someone to make immediate, irreversible decisions because something felt absolutely true during an altered state.
Integration may involve:
- Reconstructing the experience in a coherent way
- Exploring emotions, sensations, images, relationships, and themes
- Distinguishing metaphor, possibility, memory, and fact
- Identifying what feels useful and what remains uncertain
- Processing fear, shame, grief, confusion, or disappointment
- Watching for sleep disruption, mania, psychosis, dissociation, or prolonged anxiety
- Reconnecting insights with established therapeutic goals
- Choosing small behavioral experiments rather than dramatic declarations
- Supporting changes in relationships, boundaries, routines, or substance use
- Making space for creativity, somatic work, nature, journaling, or spiritual reflection
If someone realizes, “I have abandoned myself to keep relationships,” integration asks what self-loyalty looks like on an ordinary Tuesday. It might mean pausing before saying yes, speaking one honest sentence, or noticing the bodily signal that appears before self-abandonment.
Insight is meaningful. Repetition is what builds a life.
Why Integration Is Not Optional
After a profound experience, a person may feel open, energized, emotionally raw, peaceful, disoriented, or convinced that everything has changed. That period can carry opportunity and vulnerability at the same time.
Some people experience an “afterglow”—improved mood, connectedness, or motivation. Others feel tired, tender, disappointed, anxious, or flooded by material that did not resolve when the session ended. Sleep and mood can shift. Old memories may surface. Relationships may feel different.
Integration offers a place to slow the meaning-making process.
It can help prevent spiritual bypassing—the use of a transcendent idea to avoid grief, accountability, conflict, or practical change. It can also help protect against the opposite problem: dismissing a meaningful experience because it cannot be explained immediately.
The goal is not to preserve the peak state. It is to become more capable of living what was learned.
What Is Microdosing?
Microdosing generally refers to taking a small amount of a psychedelic intended to produce little or no obvious alteration in perception or functioning. People commonly report seeking improvements in mood, creativity, focus, energy, or emotional openness.
The scientific evidence is much less certain than popular accounts suggest.
A 2024 review of 19 placebo-controlled studies of low-dose LSD found a mixture of positive and null findings and raised significant questions about expectancy and blinding. Some studies report subtle effects on mood or cognition; others find that people who believe they received a microdose improve even when they received placebo.
Microdosing should therefore not be marketed as a proven treatment for depression, ADHD, anxiety, or trauma. It can still produce side effects, interact with medication, worsen anxiety or insomnia, affect cardiovascular measures, or destabilize vulnerable individuals. A dose intended to be subtle can also be stronger than expected because potency and products are often unreliable outside regulated research or service systems.
When might microdosing be considered?
Only within the bounds of applicable law and after appropriate medical and psychological review, someone might explore a low-dose approach when:
- The goal is modest observation rather than an intense altered state
- The person is medically and psychiatrically stable
- There is a clear monitoring plan
- The source and contents are regulated and known
- The person understands that evidence of benefit remains mixed
- Functioning, driving, work, parenting, and safety will not be compromised
Microdosing is not necessarily safer simply because it is lower dose. Repeated exposure introduces a different set of questions, including cumulative side effects, tolerance, sleep disturbance, medication interactions, and the possibility of using a substance to avoid rather than engage with underlying issues.
What Is a “Macrodose”?
Macrodose is an informal term, not a precise medical category. It generally refers to a dose expected to cause a clearly altered state of consciousness, with changes in perception, emotion, time, sense of self, and cognition.
Higher-dose psychedelic experiences are the focus of much of the clinical research showing therapeutic benefit. They may bring a person into contact with grief, fear, compassion, memory, meaning, or aspects of identity in an unusually vivid way.
They also carry greater acute risk.
Possible adverse effects include panic, confusion, paranoia, nausea, vomiting, headache, temporary increases in blood pressure and heart rate, impaired judgment, accidents, retraumatization, and—rarely—prolonged psychiatric or perceptual symptoms. The quality of the substance, setting, screening, supervision, and emergency capacity becomes especially important as intensity rises.
When might a higher-dose experience be considered?
A higher-dose psychedelic experience should be considered only in a lawful, appropriately regulated or research setting with:
- Thorough medical and psychological screening
- A clearly identified clinical or personal-growth rationale
- A trained, ethical, and properly authorized team
- Known substance identity and dose
- Continuous support and appropriate monitoring
- Clear consent and boundaries
- Capacity to respond to medical or psychiatric emergencies
- Transportation and aftercare plans
- Scheduled integration and follow-up
It is not appropriate simply because someone wants a breakthrough, is tired of ordinary therapy, or assumes that a larger dose will create deeper healing. More intensity is not always more therapeutic.
Who Should Not Use Psychedelics—or Should Proceed Only With Specialized Medical Evaluation?
There is no single screening list that applies equally to every psychedelic. Still, common clinical-trial exclusions and major caution areas include:
Psychiatric risks
- A personal history of schizophrenia, schizoaffective disorder, psychosis, or a psychotic-spectrum condition
- Bipolar I disorder or a history of mania; family history may also increase concern
- Current mania, psychosis, severe dissociation, or significant loss of reality testing
- Active suicidal intent, a recent suicide attempt, or an acute psychiatric crisis
- Severe emotional instability without adequate support or follow-up
- A previous prolonged or dangerous reaction to a psychedelic
People with depression or trauma are not automatically appropriate candidates. Stability, diagnostic clarity, supports, and the particular substance all matter.
Medical and medication risks
- Uncontrolled high blood pressure or significant cardiovascular disease
- Certain seizure or neurological disorders
- Pregnancy or breastfeeding
- Serious medical illness that has not been evaluated for the specific substance
- Medication combinations that may create toxicity, seizure risk, cardiovascular risk, withdrawal risk, or unpredictable effects
Lithium deserves particular caution because case reports and safety reviews have associated its combination with classic psychedelics with seizures and other serious reactions. Ayahuasca and other MAOI-containing preparations can have dangerous interactions with serotonergic and sympathomimetic drugs. Ibogaine carries distinct cardiac risks. MDMA, ketamine, psilocybin, LSD, and ayahuasca should never be treated as though they share one interaction profile.
Do not stop psychiatric or medical medication to pursue a psychedelic experience without direct guidance from the prescribing clinician.
Situational reasons to wait
Even without a formal contraindication, it may be wiser to postpone when someone:
- Is severely sleep-deprived or physically depleted
- Is in the middle of an acute relationship, legal, housing, or financial crisis
- Lacks trustworthy support afterward
- Feels pressured by a partner, therapist, facilitator, or group
- Cannot verify the identity or purity of the substance
- Is expected to keep the experience secret from essential medical providers
- Does not feel free to withdraw consent
- Has no realistic integration or emergency plan
Readiness is not the same as desperation. A person can deeply want relief and still deserve a careful process.
Ethical Care Matters
Altered states can increase suggestibility, dependency, emotional openness, and vulnerability. Ethical preparation includes discussing power—not only symptoms.
A trustworthy professional should be clear about credentials, scope, touch, confidentiality, costs, emergency procedures, substance sourcing, legal status, and what happens if the client changes their mind. They should not promise a cure, encourage secrecy, romanticize distress, initiate sexual or exploitative contact, or claim special authority over the meaning of a person’s experience.
Preparation and integration psychotherapy can be valuable even when the therapist does not provide, prescribe, recommend, source, or attend a dosing session. The role must be explicit. Supporting someone in thinking carefully and processing an experience is different from administering or facilitating a controlled substance.
What Is My Role at The Hive?
At The Hive, my role is to provide psychotherapy focused on preparation and integration—not to sell, supply, prescribe, or administer psychedelic substances.
Preparation may include exploring a person’s intentions, expectations, trauma history, current stability, support system, fears, relational patterns, and capacity to care for themselves before and after an experience. It may also include identifying questions the person should discuss with an appropriate medical provider or legally authorized facilitator.
Integration begins with curiosity rather than certainty. We may explore what arose emotionally, physically, relationally, or symbolically; distinguish insight from impulse; and ask how something meaningful can become a grounded change in daily life. My trauma-informed, relational, somatic, and Brainspotting background can help clients notice not only what they think the experience meant, but also what continues to live in the body.
I do not assume that every psychedelic experience was wise, therapeutic, or factually accurate. I also do not dismiss an experience simply because it occurred in an altered state. Together, we slow it down, respect uncertainty, and look for what supports greater truth, responsibility, safety, and sustainable change.
The Medicine Is Not the Whole Treatment
Psychedelics may open a door. They do not decide what happens next.
The therapeutic potential lies not only in altered perception, emotional intensity, or neurobiology. It also lies in the quality of the container: honest screening, informed consent, preparation, relational safety, ethical support, and integration into daily life.
A single experience cannot do the work of every boundary, repair every relationship, or build every new habit. It may illuminate what needs attention. It may loosen a pattern or make another way of living feel possible.
Preparation asks: How do we approach this responsibly?
Integration asks: How will you live what you learned?
Both questions belong at the center of the work.
About The Hive
Meg Reinis, LMFT, is the founder of The Hive Therapy & Wellness Boutique. Her interest in psychedelic preparation and integration is informed by personal experience, continued study, and more than 20 years of clinical work. She offers trauma-informed psychotherapy focused on safety, meaning-making, the nervous system, relationships, and sustainable change.
This article is educational and does not constitute medical advice, legal advice, a recommendation to use psychedelics, or an offer to provide or facilitate controlled substances. Laws and clinical guidance change. Psychedelics remain federally controlled in many circumstances, and FDA approval, state authorization, research participation, and personal possession are legally distinct. Consult appropriately licensed medical, psychiatric, legal, and regulated natural-medicine professionals.
Research and Official Guidance Referenced
- U.S. Food and Drug Administration. Psychedelic Drugs: Considerations for Clinical Investigations. Final Guidance, July 2026. fda.gov
- Thal SB, et al. Therapeutic (Sub)stance: Current Practice and Therapeutic Conduct in Preparatory Sessions in Substance-Assisted Psychotherapy—A Systematized Review. Journal of Psychopharmacology. 2022. pubmed.ncbi.nlm.nih.gov/36263882
- Greń J, et al. Back From the Rabbit Hole: Theoretical Considerations and Practical Guidelines on Psychedelic Integration for Mental Health Specialists. 2023. pubmed.ncbi.nlm.nih.gov/37904908
- Metaxa AM, Clarke M. Efficacy of Psilocybin for Treating Symptoms of Depression: Systematic Review and Meta-Analysis. BMJ. 2024. pubmed.ncbi.nlm.nih.gov/38692686
- Yerubandi A, et al. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Network Open. 2024. pubmed.ncbi.nlm.nih.gov/38598236
- Polito V, Liknaitzky P. Is Microdosing a Placebo? A Rapid Review of Low-Dose LSD and Psilocybin Research. 2024. pubmed.ncbi.nlm.nih.gov/38877715
- Colorado Department of Regulatory Agencies. Natural Medicine Frequently Asked Questions. dpo.colorado.gov/NaturalMedicine/FAQ